Other factors that correlated with the ability to achieve the treatment goal were a premature history of coronary artery disease (p = 0.002), history of myocardial infarction (p = 0.02), history of revascularization (p = 0.04), treatment with angiotensin-converting enzyme inhibitors (ACE-I) (p = 0.02), and treatment with ezetimibe (p = 0.01) and with PCSK9 inhibitors (p = 0.002). The gene discussed is ACE; the disease is myocardial infarction.